Androgen replacement therapy in women

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 5, 2012, Pages 515-529

  Lebbe, Marie ^a   Hughes, David ^a   Reisch, Nicole ^b   Arlt, Wiebke ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

androgen deficiency; androgens; DHEA; female sexuality; postmenopause; testosterone

Indexed keywords

ALBUMIN; ANDROFEME; ANDROGEN; ANDROGEN RECEPTOR; COMBINED ESTERIFIED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN DERIVATIVE; ESTRONE; GESTAGEN; GLUCOCORTICOID; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; MINERALOCORTICOID; PLACEBO; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ACNE; ADRENAL INSUFFICIENCY; ALBUMIN BLOOD LEVEL; ALOPECIA; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; ANDROGEN SYNTHESIS; ANDROGEN THERAPY; ATHEROSCLEROSIS; BLOOD SAMPLING; BREAST CANCER; CLINICAL ASSESSMENT; COHORT ANALYSIS; CORTICOSTEROID BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; EVIDENCE BASED MEDICINE; FEMALE; FEMALE ANDROGEN DEFICIENCY; FEMALE ANDROGEN DEFICIENCY SYNDROME; FEMALE SEXUAL DYSFUNCTION; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPOACTIVE SEXUAL DESIRE DISORDER; INCIDENCE; LIBIDO DISORDER; LIFESPAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MENOPAUSAL SYNDROME; MENOPAUSE; OBESITY; OVARY FOLLICLE; PARACRINE SIGNALING; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOM; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

EID: 84867631813     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.45     Document Type: Review

References (137)

1. Arlt W. Androgen therapy in women. Eur. J. Endocrinol. 154 (1), 1-11 (2006).
2. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog. Brain Res. 182, 97-148 (2010).
3. Longscope C. Dehydroepiandrosterone metabolism. J. Endocrinol. 150, S125 (1996).
4. Grino PB, Griffi n JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126 (2), 1165-1172 (1990). (Pubitemid 20079537)
5. Hammer F, Subtil S, Lux P et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 90 (6), 3600-3605 (2005). (Pubitemid 41014332)
6. Arlt W, Justl HG, Callies F et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J. Clin. Endocrinol. Metab. 83 (6), 1928-1934 (1998). (Pubitemid 28496318)
7. Nakamura Y, Hornsby PJ, Casson P et al. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J. Clin. Endocrinol. Metab. 94 (6), 2192-2198 (2009).
8. Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 18 (1), 30-43 (2011).
9. Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgenproducing gland. Fertil. Steril. 62, 20-27 (1994). (Pubitemid 24198053)
10. Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39 (6), 1020-1024 (1974).
11. Idkowiak J, Lavery GG, Dhir V et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur. J. Endocrinol. 165 (2), 189-207 (2011).
12. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 90 (7), 3847-3853 (2005). (Pubitemid 41058142)
13. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59 (3), 551-555 (1984). (Pubitemid 14031806)
14. Spencer JB, Klein M, Kumar A, Azziz R. The age-associated decline of androgens in reproductive age and menopausal Black and White women. J. Clin. Endocrinol. Metab. 92 (12), 4730-4733 (2007). (Pubitemid 350223451)
15. Arlt W. Dehydroepiandrosterone and ageing. Best Pract. Res. Clin. Endocrinol. Metab. 18 (3), 363-380 (2004). (Pubitemid 38992417)
16. De Gendt K, Verhoeven G. Tissue- and cell-specifi c functions of the androgen receptor revealed through conditional knockout models in mice. Mol. Cell. Endocrinol. 352 (1-2), 13-25 (2012).
17. Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol. Reprod. 78 (3), 380-389 (2008). (Pubitemid 351416471)
18. Bancroft J. Sexual effects of androgens in women: some theoretical considerations. Fertil. Steril. 77 (Suppl. 4), S55-S59 (2002). (Pubitemid 34467055)
19. Sarrel PM. Psychosexual effects of menopause: role of androgens. Am. J. Obstet. Gynecol. 180 (3 Pt 2), S319-S324 (1999). (Pubitemid 29149111)
20. Ebinger M, Sievers C, Ivan D, Schneider HJ, Stalla GK. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J. Psychopharmacol. (Oxford) 23 (7), 841-853 (2009).
21. Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 95 (10), 4542. 4548 (2010).
22. Janse F, Eijkemans MJ, Goverde AJ et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur. J. Endocrinol. 165 (6), 925. 933 (2011).
23. Stanczyk FZ. Measurement of androgens in women. Semin. Reprod. Med. 24 (2), 78. 85 (2006). (Pubitemid 43736518)
24. Kushnir MM, Blamires T, Rockwood AL et al. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56 (7), 1138. 1147 (2010).
25. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53 (1), 58. 68 (1981). (Pubitemid 13245381)
26. Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J. Androl. 13 (2), 107. 116 (1992).
27. Emadi-Konjin P, Bain J, Bromberg IL. Evaluation of an algorithm for calculation of serum-bioavailableh testosterone (BAT). Clin. Biochem. 36 (8), 591. 596 (2003). (Pubitemid 37434024)
28. Bachmann G, Bancroft J, Braunstein G et al. Princeton. Female androgen insuffi ciency: the Princeton consensus statement on defi nition, classifi cation, and assessment. Fertil. Steril. 77 (4), 660. 665 (2002). (Pubitemid 34275339)
29. Burger HG, Papalia MA. A clinical update on female androgen insuffi ciency. testosterone testing and treatment in women presenting with low sexual desire. Sex. Health 3 (2), 73. 78 (2006). (Pubitemid 43829302)
30. Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: defi nitions and classifi cations. J. Urol. 163 (3), 888. 893 (2000). (Pubitemid 30091640)
31. Geiss IM, Umek WH, Dungl A, Sam C, Riss P, Hanzet al. Prevalence of female sexual dysfunction in gynecologic and urogynecologic patients according to the international consensus classifi cation. Urology 62 (3), 514. 518 (2003). (Pubitemid 36999879)
32. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281 (6), 537. 544 (1999). (Pubitemid 29081307)
33. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and selfreported sexual function in women. JAMA 294 (1), 91. 96 (2005). (Pubitemid 41002843)
34. Wierman ME, Basson R, Davis SR et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab. 91 (10), 3697. 3710 (2006). (Pubitemid 44536831)
35. Judd HL. Hormonal dynamics associated with the menopause. Clin. Obstet. Gynecol. 19 (4), 775. 788 (1976). (Pubitemid 8007370)
36. Nathorst-Boos J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol. Obstet. Invest. 34 (2), 97. 101 (1992).
37. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343 (10), 682. 688 (2000).
38. Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 105 (5 Pt 1), 944. 952 (2005). (Pubitemid 40571010)
39. Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90 (9), 5226. 5233 (2005). (Pubitemid 41262278)
40. Arlt W. Androgen replacement therapy in women. Curr. Opin. Investig. Drugs 6 (10), 1028. 1036 (2005). (Pubitemid 41535787)
41. Davis SR, Moreau M, Kroll R et al. APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. (19), 2005. 2017 (2008).
42. Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 13 (2), 121. 131 (2010).
43. Penteado SR, Fonseca AM, Bagnoli VR, Abdo CH, Junior JM, Baracat EC. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric 11 (1), 17. 25 (2008).
44. Barrett-Connor E, Young R, Notelovitz M et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profi les. J. Reprod. Med. 44 (12), 1012. 1020 (1999). (Pubitemid 30030175)
45. Braunstein GD, Sundwall DA, Katz M et al. Safety and effi cacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. 165 (14), 1582. 1589 (2005). (Pubitemid 41124151)
46. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin. Endocrinol. (Oxf) 57 (2), 209. 214 (2002). (Pubitemid 34989097)
47. Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterifi ed estrogens compared with esterifi ed estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J. Clin. Endocrinol. Metab. 89 (5), 2207. 2213 (2004). (Pubitemid 38619854)
48. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21 (3), 227. 236 (1995).
49. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 7 (6), 395. 401 (2000).
50. Davis SR, van der Mooren MJ, van Lunsen RH et al. Effi cacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13 (3), 387. 396 (2006).
51. Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J. Clin. Endocrinol. Metab. 94 (12), 4907-4913 (2009).
52. de Paula FJ, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefi ts of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 56 (1), 69-77 (2007).
53. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J. Clin. Endocrinol. Metab. 87 (4), 1509-1516 (2002). (Pubitemid 34615230)
54. El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebocontrolled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 10 (4), 335-343 (2007). (Pubitemid 47123955)
55. Flöter A, Nathorst-Böös J, Carlström K, Ohlsson C, Ringertz H, Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol. Endocrinol. 20 (3), 155-160 (2005).
56. Nathorst-Böös J, Jarkander-Rolff M, Carlström K, Flöter A, von Schoultz B. Percutaneous administration of testosterone gel in postmenopausal women-a pharmacological study. Gynecol. Endocrinol. 20 (5), 243-248 (2005).
57. Hofl ing M, Lundström E, Azavedo E, Svane G, Hirschberg AL, von Schoultz B. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 10 (2), 155-163 (2007). (Pubitemid 46482169)
58. Hofl ing M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogeninduced breast cell proliferation in postmenopausal women. Menopause 14 (2), 183-190 (2007). (Pubitemid 46673468)
59. Penotti M, Sironi L, Cannata L et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil. Steril. 76 (2), 235-240 (2001).
60. Raisz LG, Wiita B, Artis A et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 81 (1), 37-43 (1996). (Pubitemid 26035768)
61. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom. Med. 47 (4), 339-351 (1985).
62. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 10 (3), 325-335 (1985). (Pubitemid 16237741)
63. Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13 (5), 770-779 (2006).
64. Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ; ESTRATEST Clinical Study Group. Combined esterifi ed estrogens and methyltestosterone versus esterifi ed estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 12 (4), 374-384 (2005). (Pubitemid 41098650)
65. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipidlipoprotein profi les in surgical menopause. Obstet. Gynecol. 85 (4), 529-537 (1995).
66. Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil. Steril. 86 (1), 136-144 (2006).
67. Arrington R, Cofrancesco J, Wu AW. Questionnaires to measure sexual quality of life. Qual. Life Res. 13 (10), 1643-1658 (2004). (Pubitemid 41215245)
68. Benetti-Pinto CL, Bedone AJ, Magna LA. Evaluation of serum androgen levels in women with premature ovarian failure. Fertil. Steril. 83 (2), 508-510 (2005).
69. Bachelot A, Meduri G, Massin N, Misrahi M, Kuttenn F, Touraine P. Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure. J. Clin. Endocrinol. Metab. 90 (4), 2391-2396 (2005). (Pubitemid 40586289)
70. Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 94 (12), 4820-4827 (2009).
71. Hahner S, Loeffl er M, Fassnacht M et al. Impaired subjective health status in 256 patients with adrenal insuffi ciency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92 (10), 3912-3922 (2007). (Pubitemid 47607641)
72. Erichsen MM, Løvås K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insuffi ciency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 94 (12), 4882-4890 (2009).
73. Jakobi JM, Killinger DW, Wolfe BM, Mahon JL, Rice CL. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle Nerve 24 (8), 1040-1049 (2001). (Pubitemid 32656190)
74. Arlt W, Callies F, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insuffi ciency. N. Engl. J. Med. 341 (14), 1013-1020 (1999). (Pubitemid 29451796)
75. Callies F, Fassnacht M, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insuffi ciency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J. Clin. Endocrinol. Metab. 86 (5), 1968-1972 (2001). (Pubitemid 32472906)
76. Bilger M, Speraw S, LaFranchi SH, Hanna CE. Androgen replacement in adolescents and young women with hypopituitarism. J. Pediatr. Endocrinol. Metab. 18 (4), 355-362 (2005). (Pubitemid 40520628)
77. Brooke AM, Kalingag LA, Miraki-Moud F et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J. Clin. Endocrinol. Metab. 91 (10), 3773-3779 (2006). (Pubitemid 44536842)
78. Hunt PJ, Gurnell EM, Huppert FA et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 85 (12), 4650-4656 (2000). (Pubitemid 32157648)
79. Johannsson G, Burman P, Wirén L et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgendefi cient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. 87 (5), 2046-2052 (2002). (Pubitemid 34525078)
80. Libè R, Barbetta L, Dall'Asta C et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J. Endocrinol. Invest. 27 (8), 736-741 (2004). (Pubitemid 39619060)
81. Løvås K, Husebye ES. Replacement therapy in Addison's disease. Expert Opin. Pharmacother. 4 (12), 2145-2149 (2003). (Pubitemid 37541228)
82. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54 (3), 765-769 (2005).
83. Dhatariya KK, Greenlund LJ, Bigelow ML et al. Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin. Proc. 83 (11), 1218-1225 (2008).
84. Gurnell EM, Hunt PJ, Curran SE et al. Long-term DHEA replacement in primary adrenal insuffi ciency: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 93 (2), 400-409 (2008). (Pubitemid 351240809)
85. van Thiel SW, Romijn JA, Pereira AM et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insuffi ciency: a randomized, placebo-controlled, cross-over trial. J. Clin. Endocrinol. Metab. 90 (6), 3295-3303 (2005). (Pubitemid 41014289)
86. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab. 82 (10), 3498-3505 (1997). (Pubitemid 27419111)
87. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 63 (3), 240-245 (2009).
88. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J. Clin. Endocrinol. Metab. 96 (6), 1642-1653 (2011).
89. Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 66 (2), 172-179 (2010).
90. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78 (6), 1360-1367 (1994). (Pubitemid 24181005)
91. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J. Clin. Endocrinol. Metab. 84 (5), 1527-1533 (1999). (Pubitemid 30644248)
92. Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA 97 (8), 4279-4284 (2000).
93. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med. 355, 1647-1659 (2006). (Pubitemid 44583955)
94. Arlt W. Dehydroepiandrosterone replacement therapy. Semin. Reprod. Med. 22 (4), 379-388 (2004).
95. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8 (3), 181-187 (1999). (Pubitemid 29186836)
96. Hazeldine J, Arlt W, Lord JM. Dehydroepiandrosterone as a regulator of immune cell function. J. Steroid Biochem. Mol. Biol. 120 (2-3), 127-136 (2010).
97. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 15 (10), 2129-2132 (2000).
98. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil. Steril. 84 (3), 756 (2005).
99. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 21 (11), 2845-2849 (2006). (Pubitemid 44566996)
100. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 25 (10), 2496-2500 (2010).
101. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod. Biomed. Online 21 (3), 360-365 (2010).
102. Sunkara SK, Coomarasamy A. Androgen pretreatment in poor responders undergoing controlled ovarian stimulation and in vitro fertilization treatment. Fertil. Steril. 95 (8), e73-e74; author reply e75 (2011).
103. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 17 (9), 67 (2011).
104. Davis S. Testosterone defi ciency in women. J. Reprod. Med. 46 (Suppl. 3), 291-296 (2001).
105. Arlt W, Haas J, Callies F et al. Biotransformation of oral dehydroepiandrosterone in elderly men: signifi cant increase in circulating estrogens. J. Clin. Endocrinol. Metab. 84 (6), 2170-2176 (1999). (Pubitemid 30647050)
106. Swerdloff RS, Wang C, Cunningham G et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85 (12), 4500-4510 (2000). (Pubitemid 32157624)
107. Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J. Clin. Endocrinol. Metab. 83 (11), 3920-3924 (1998). (Pubitemid 28513573)
108. Singh AB, Lee ML, Sinha-Hikim I et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 91 (1), 136-144 (2006). (Pubitemid 43069129)
109. Nachtigall L, Casson P, Lucas J, Schofi eld V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol. Endocrinol. 27 (1), 39-48 (2011).
110. Schover LR. Androgen therapy for loss of desire in women: is the benefi t worth the breast cancer risk? Fertil. Steril. 90 (1), 129-140 (2008).
111. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94 (8), 606-616 (2002). (Pubitemid 34498648)
112. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol. 630, 148-165 (2008).
113. Kaaks R, Rinaldi S, Key TJ et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr. Relat. Cancer 12 (4), 1071-1082 (2005).
114. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 96 (24), 1856-1865 (2004). (Pubitemid 40081323)
115. Zeleniuch-Jacquotte A, Shore RE, Koenig KL et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br. J. Cancer 90 (1), 153-159 (2004).
116. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch. Intern. Med. 166 (14), 1483-1489 (2006). (Pubitemid 44125867)
117. Ness RB, Albano JD, McTiernan A, Cauley JA. Infl uence of estrogen plus testosterone supplementation on breast cancer. Arch. Intern. Med. 169 (1), 41-46 (2009).
118. Danforth KN, Eliassen AH, Tworoger SS et al. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int. J. Cancer 126 (1), 199-207 (2010).
119. Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J. Clin. Endocrinol. Metab. 94 (12), 4907-4913 (2009).
120. McCormack VA, Dowsett M, Folkerd E et al. Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res. 11 (3), R38 (2009).
121. Helzlsouer KJ, Alberg AJ, Gordon GB et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274 (24), 1926-1930 (1995). (Pubitemid 26003062)
122. Lukanova A, Lundin E, Akhmedkhanov A et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int. J. Cancer 104 (5), 636-642 (2003).
123. Rinaldi S, Dossus L, Lukanova A et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol. Biomarkers Prev. 16 (1), 23-29 (2007). (Pubitemid 46174259)
124. Tworoger SS, Lee IM, Buring JE, Hankinson SE. Plasma androgen concentrations and risk of incident ovarian cancer. Am. J. Epidemiol. 167 (2), 211-218 (2008).
125. Li AJ, Karlan BY. Androgens and epithelial ovarian cancer: What's the connection? Cancer Biol. Ther. 7 (11), 1712-1716 (2008).
126. Allen NE, Key TJ, Dossus L et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer 15 (2), 485-497 (2008). (Pubitemid 351880837)
127. Bernini GP, Sgro' M, Moretti A et al. Endogenous androgens and carotid intimal-medial thickness in women. J. Clin. Endocrinol. Metab. 84 (6), 2008-2012 (1999). (Pubitemid 30647026)
128. Kiechl S, Willeit J, Bonora E, Schwarz S, Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arterioscler. Thromb. Vasc. Biol. 20 (4), 1094-1100 (2000).
129. Bernini GP, Moretti A, Sgró M et al. Infl uence of endogenous androgens on carotid wall in postmenopausal women. Menopause 8 (1), 43-50 (2001).
130. Golden SH, Maguire A, Ding J et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am. J. Epidemiol. 155 (5), 437-445 (2002). (Pubitemid 34174155)
131. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur. J. Endocrinol. 156 (6), 687-693 (2007). (Pubitemid 46952539)
132. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr. Metab. Cardiovasc. Dis. 17 (10), 705-711 (2007). (Pubitemid 350103758)
133. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J. Clin. Endocrinol. Metab. 93 (1), 131-138 (2008).
134. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH; atherosclerosis risk in communities study. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J. Clin. Endocrinol. Metab. 90 (2), 1202-1209 (2005). (Pubitemid 40279255)
135. Lambrinoudaki I, Christodoulakos G, Rizos D et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur. J. Endocrinol. 154 (6), 907-916 (2006). (Pubitemid 43997731)
136. Manolakou P, Angelopoulou R, Bakoyiannis C, Bastounis E. The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression. Reprod. Biol. Endocrinol. 7, 44 (2009).
137. Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J. Sex. Med. 7 (1 Pt 2), 314-326 (2010).